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Summary
Background:  The  Gram-negative  pathogenic  bacteria  Klebsiella  oxytoca  and  Kleb-
siella  pneumoniae  produce  the  extended  spectrum  -lactamase  (ESBL)  and
cephalosporinase  enzymes  and  are  the  major  causes  of  hospital  acquired  (HA)  infec-
tions  and  epidemics  in  non-hygienic  communities  in  the  majority  of  developing
countries.
Methods:  The  prevalence  of  multidrug  resistance  among  445  strains  of  K.  oxytoca
and  K.  pneumoniae  isolated  from  clinical  samples  of  patients  with  gastrointestinal
infections  over  a  period  of  42  months  in  the  hospital  was  recorded,  along  with  the
sensitivity  patterns  to  23  antibiotics,  including  third-generation  cephalosporin  and
ﬂuoroquinolone  antibiotics,  using  the  disk-diffusion  method.
Results:  Of  175  K.  oxytoca  isolates,  143  were  ESBL  positive  and  117  were  ﬂuoro-
quinolone  resistant.  Of  270  K.  pneumoniae  isolates,  200  were  ESBL  positive  and
195  were  independently  ﬂuoroquinolone  resistant.  The  HA  samples  yielded  more
isolates  than  the  community  acquired  (CA)  samples  for  each  species.  The  K.  oxy-
toca  strains  were  resistant  to  cefepime,  gatiﬂoxacin,  ciproﬂoxacin,  ceftazidime,
levoﬂoxacin  and  imipenem,  whereas  the  K.  pneumoniae  strains  were  highly  resis-
tant  to  ampicillin,  norﬂoxacin,  ciproﬂoxacin,  gatiﬂoxacin,  oﬂoxacin,  amoxyclav,
ceftazidime,  cefepime,  ceﬁxime,  piperacillin  and  imipenem.  The  ESBL-producing
and  ﬂuoroquinolone-resistant  K.  pneumoniae  strains  were  more  prevalent  than  the
K.  oxytoca  strains  in  the  HA/CA  samples.  The  minimum  inhibitory  concentration
values  of  the  third-generation  cephalosporins:  cefotaxime  and  ceftazidime  and  the
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ﬂuoroquinolones:  ciproﬂoxacin  and  levoﬂoxacin  against  both  species  of  Klebsiella
conﬁrmed  the  resistance  in  the  current/coveted  treatment  options.
Conclusions:  Patients  with  other  bacterial  infections  had  a  relatively  higher  probabil-
L-producing  and  ﬂuoroquinolone-resistant  Klebsiella  strains.
 highlight  the  alarming  state  of  Klebsiella  infection  dynamics
ining  communities.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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that plasmid-mediated  quinolone-resistant  deter-
minants, namely  qnrB1,  qnrS1,  were  isolated  fromity  of  infection  with  ESB
The  data  presented  here
in  the  hospital  and  adjo
©  2014  King  Saud  Bin  Ab
Ltd.  All  rights  reserved.
ntroduction
urveillance  of  the  Gram-negative  (GN)  pathogenic
acteria Klebsiella  oxytoca  and  Klebsiella  pneumo-
iae (tribe  Klebsiellae,  family  Enterobacteriaceae)
hat produce  extended  spectrum  -lactamase
ESBL) and  cephalosporinase  enzymes  is  a  respon-
ibility  of  hospital  management.  These  enzymes
roduced by  several  strains  of  both  species
ause resistance  to  penicillin  derivatives  includ-
ng the  third-generation  cephalosporins  (3GCs)  and
onobactams,  rendering  these  species  notorious
athogens [1—3]. Control  measures  remain  difﬁcult
or a  clinician/hospital  epidemiologist  depending
n the  extent  of  drug  resistance  to  other  classes
f antibiotics,  both  empirically  and  routinely  after
scertaining  the  antibiograms  of  isolates  in  vitro.
y producing  ESBL  and  cephalosporinase  enzymes
nd also  using  other  mechanisms,  multidrug-
esistant (MDR)  Klebsiella  strains  cause  frequent
rievous bacteremia/septicemia.  For  example,
atal neonatal  septicemia  caused  by  a  metallo-
-lactamase-producing  K.  pneumoniae  strain  was
eported  locally  [4]. Indeed,  GN  bacteria  resistant
o all  major  classes  of  antibiotics  have  emerged
s intense  pandrug-resistant  (PDR)  bacteria.  PDR
trains of  Pseudomonas  aeruginosa, Acinetobacter
aumannii and  K.  pneumoniae  cause  comorbidities
nd immature  mortality  [5].  However,  the  term  PDR
as not  yet  reached  a  consensus  in  the  literature,
espite its  clear  etymological  meanings,  ‘resistant
o almost  all  commercially  available  antimicro-
ials’, ‘resistant  to  all  antimicrobials  routinely
ested’ and  ‘resistant  to  all  antibiotic  classes  avail-
ble for  empiric  treatment’.  Klebsiella  sp.  colonize
he respiratory,  gastrointestinal  and  urinary  tracts.
The variant  CTX-M  (resistant  to  cefotaxime)
ype -lactamase  is  the  predominant  ESBL  vari-
nt,  compared  to  the  other  variants,  such  as
emoneira  (TEM)  and  sulfhydryl  variable  (SHV)
ypes, of  ESBLs  [6]. These  two  Klebsiella  species,
long with  Escherichia  coli  and  Proteus  mirabilis
nd a  few  members  of  the  Enterobacteriaceae,
uch  as  Citrobacter  sp.,  Serratia  sp.  and  Morganella
organii with  ESBL-producing  capacity,  have  been
t
t
didely  reported  and  cause  longer  hospitalization,
omorbidities  and  fatality  with  frequent  failures  of
mpiric therapy  [3,7—9].  Therefore,  ESBL  produc-
ion is  now  widespread  in  the  family.
For the  control  of  Enterobacteriaceae
athogens,  a  cephalosporin  antibiotic,  such  as
efepime,  ceftriaxone,  cefotaxime,  ceftazidime,
efpodoxime and  ceﬁxime,  or  ﬂuoroquinolones,
uch as  gatiﬂoxacin,  moxiﬂoxacin,  ciproﬂoxacin,
evoﬂoxacin, temaﬂoxacin,  grepaﬂoxacin  and
rovaﬂoxacin,  are  often  used  empirically.  Fluo-
oquinolones  are  effective  for  bacterial  control
y interfering  with  the  bacterial  DNA  gyrase  and
opoisomerase  IV.  These  broad-spectrum  antibi-
tics are  even  used  against  Staphylococcus  aureus
nd other  Gram-positive  (GP)  bacteria.  Because
f the  adverse  effects  on  the  host  caused  by  the
atter three  ﬂuoroquinolones,  new  antibiotics  are
ontinually developed.  However,  resistance  to
uoroquinolones  by  Enterobacteriaceae  members
s widespread  [10].  The  resistance  mechanisms
nclude alterations  in  the  drug  target  and/or  in
he permeation  of  the  drug  to  reach  the  target.
dditionally, enroﬂoxacin  (ﬂuoroquinolone)  is
egraded by  the  fungus  Gloeophyllum  striatum  in
ixed infections  [11]. Enroﬂoxacin  metabolism  by
he fungus  Mucor  ramannianus  was  also  reported.
uring a  21-day  incubation,  78%  of  the  enroﬂoxacin
as transformed  into  three  metabolites,  namely
nroﬂoxacin  N-oxide  (62%),  N-acetyl  ciproﬂoxacin
8.0%), and  desethylene-enroﬂoxacin  (3.5%).  The
ajor metabolite  of  enroﬂoxacin  in  animals  is
iproﬂoxacin,  produced  by  N-deethylation  of  the
thylpiperazine  ring  [12].  For  example,  the  major-
ty of  strains  of  11  different  GN  bacteria  isolated
rom rectal  swabs  from  a  large  number  of  patients
n the  intensive  care  unit  (ICU)  of  a hospital  in
stanbul  revealed  that  40%  of  the  isolates  were
esistant to  ciproﬂoxacin.  The  study  determinedhe isolates  [13].
Moreover,  approximately  150  types  of  ESBL  bac-
erial strains  have  been  described  with  a worldwide
istribution, clearly  demonstrating  that  -lactam
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antibiotic  resistance  emerged  in  geographic  zones
where  the  particular  antibiotic  was  ﬁrst  used
[14,15].  Speciﬁcally,  in  a  study  with  K.  pneumo-
niae, it  was  reported  that  ciproﬂoxacin  use  and
ESBL production  are  related  [15],  conﬁrming  that
the use  of  a  particular  antibiotic  induces  resis-
tance to  it  in  the  target  pathogen.  Furthermore,
Enterobacteriaceae  that  cause  urinary  tract  infec-
tions (UTIs)  that  are  resistant  to  ﬂuoroquinolone
and cephem  are  often  obtained  from  the  urine  sam-
ples of  women  with  cases  of  uncomplicated  UTI
[16].  Therefore,  the  extent  of  multidrug  resistance
in any  pathogen  is  a  signiﬁcant  obstacle  for  con-
trol in  vivo.  Unfortunately,  virulent  enteric  bacteria
such as  Klebsiella  sp.  and  E.  coli  are  present  in
non-hygienic  dwellings,  and  infection  with  these
bacteria  is  often  the  cause  of  high  infant  mortality
and outbreaks  of  infrequent  epidemics  in  develop-
ing countries  [17].
The  current  study  provides  systematic  informa-
tion on  445  strains  of  two  species  of  Klebsiella
isolated from  clinical  samples  of  patients  with  gas-
trointestinal  infections  over  a  period  of  42  months
in a  hospital.  The  antibiotic-resistant  patterns  for
the 23  antibiotics  used  in  the  study  indicate  the
alarming  state  of  the  infection  dynamics  of  MDR
strains  of  K.  oxytoca  and  K.  pneumoniae  in  a
central  Indian  state.  In  particular,  resistance  to
cephalosporin  and  ﬂuoroquinolone  antibiotics  is
reported in  this  study.  Clearly,  surveillance  in  a
hospital and  identiﬁcation  of  the  organism  caus-
ing an  ailment  is  necessary  for  clinical  stewardship.
This Indian  state  is  more  poverty-stricken  than  the
national average  because  of  urban-slum  ghettos
and under-developed  aboriginal  pockets.  This  study
identiﬁes the  actual  prevalence  of  enteropathogens
that cause  signiﬁcant  under-5  mortality  and  life-
threatening  situations  in  adults  [14]. Furthermore,
this study  is  as  an  example  of  research  that  cannot
usually  be  performed  unless  one  is  a  clinical  micro-
biologist. This  work  should  help  revise  the  antibiotic
policy of  the  state.
Methods
Isolation, identiﬁcation and antibiotic
sensitivity of bacterial isolates
Over  42  months  (July  2010—December  2013),  a
total of  1645  clinical  samples,  including  urine,  stool
and rectal  swabs,  were  collected  from  hospital-
ized patients  as  hospital  acquired  (HA,  patients
who were  admitted  for  more  than  48  h  with
no prior  enteropathogenic  infection)  samples  and
i
t
a
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utdoor  patients  as  community  acquired  (CA).  The
A patients  complained  of  diarrhea,  dysentery
nd other  associated  symptoms.  The  samples  were
ent directly  to  the  department  of  microbiology
ithin 30  min  of  collection  for  culturing,  identiﬁ-
ation and  monitoring  of  antibiotic  sensitivity.  The
solated strains  were  identiﬁed  by  standard  bio-
hemical  tests.  Antibiotic  susceptibility  tests  were
erformed  using  the  Kirby—Bauer  disk  diffusion
ethod [14]. Strain  no.  2275  of  K.  oxytoca  and
train no.  4031  of  K. pneumoniae  from  the  Micro-
ial Type  Culture  Collection  (MTCC)  were  used  as
eference  strains.
etection of ESBL producers
 double-disk-diffusion-synergy  test  was  used  for
he determination  of  ESBL  producers  in  both  Kleb-
iella species.  In this  test,  synergy  was  determined
etween a  disk  of  augmentin  (a  combination  of  20  g
moxicillin and  10  g  clavulanic  acid)  and  two  discs
f the  third-generation  cephalosporin  antibiotics
eftazidime (30  g)  and  cefotaxime  (30  g),  all  placed
n equidistant  30  mm  apart  on  the  lawn  culture  of
 test  bacterium  on  a Mueller-Hinton  (MH,  HiMedia)
gar plate  in  duplicate.  The  test  bacterium  was  con-
idered ESBL  producing  when  the  inhibition-zone
ize around  both/one  test  antibiotic  discs  increased
oward  the  augmentin  disk  because  the  clavulanic
cid in  the  augmentin  disk  was  inactivated  by  the
SBL enzyme  produced  by  the  test  bacterium  [18].
etermination of MIC values
or  conﬁrmation  and  quantitative  analysis  of  the
SBL strains,  a  96-well  micro-titer  plate  was  used
o determine  the  minimum  inhibitory  concentration
MIC) values  of  the  third-generation  cephalosporins
efotaxime and  ceftazidime  in  broth  cultures  for
00 selected  MDR  strains  of  K.  oxytoca  and  K.  pneu-
oniae  each,  of  which  50  were  ESBL  producers
nd 50  were  non-ESBL  producers.  An  exponential
ulture of  a  test  strain  in  MH  broth  was  diluted
ith normal  saline  to  obtain  a level  equivalent
o the  0.5  McFarland  standards.  To  an  aliquot  of
0 l  of  overnight  grown  test  culture,  an  aliquot
f 100  l  antibiotic  (cefotaxime  or  ceftazidime)
tock solution  of  1024  g/ml  and  0.1  ml  MH  broth
ere added  to  the  second  well  of  the  micro-
iter plate.  These  solutions  were  two-fold  serially
iluted  in  each  adjacent  well  until  a ﬁnal  con-
entration of  0.25  g/ml  antibiotic  was  achieved
n the  12th  well.  Finally,  5  l  of  0.5%  2,3,5-
riphenyltetrazolium  chloride  (TTC)  was  added  as
n indicator  of  bacterial  growth,  and  the  micro-
iter plate  was  incubated  at  37 ◦C for  18  h.  The
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Table  1  Occurrence  of  Klebsiella  oxytoca  and  Klebsiella  pneumoniae  in  clinical  samples  obtained  during  January
2010—June  2013.
Period  K.  oxytoca  K.  pneumoniae
HA  CA  HA  CA
Jul  2010—Dec  2010 19  (15)  [13] 15  (09)  [11] 22  (15)  [19] 17  (15)  [10]
Jan  2011—Jun  2011  11  (05)  [06]  09  (04)  [04]  28  (19)  [23]  19  (11)  [08]
Jul  2011—Dec  2011  15  (07)  [11]  12  (09)  [07]  30  (22)  [18]  17  (12)  [11]
Jan  2012—Jun  2012  12  (07)  [08]  03  (03)  [02]  27  (22)  [20]  10  (10)  [03]
Jul  2012—Dec  2012  16  (11)  [12]  12  (05)  [07]  18  (11)  [13]  18  (09)  [14]
Jan  2013—Jun  2013  18  (12)  [14]  11  (04)  [08]  21  (14)  [14]  13  (17)  [18]
Jul  2013—Dec  2013  15  (10)  [07]  07  (03)  [07]  15  (10)  [13]  15  (13)  [11]
Total 106  (67)  [71]  69  (37)  [46]  161  (113)  [120]  109  (87)  [75]
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oHA, hospital acquired; CA, community acquired. Numbers in p
in square bracket represent number of ﬂuoroquinolone resista
ells  were  examined  for  the  absence  of  pink  color
bacterial  growth)  in  a  well  with  the  speciﬁc  dilu-
ion,  which  was  recorded  as  the  MIC  value.  The
rst well  of  the  micro-titer  plate  was  the  con-
rol without  any  antibiotic  solution.  The  results
ere interpreted  basing  on  the  revised  break-point
alues of  the  third-generation  cephalosporin  antibi-
tics according  to  speciﬁcations  of  the  European
ommittee on  Antimicrobial  Susceptibility  Test-
ng (EUCAST)  2013  [19]. The  reference  strain  and
ll isolated  K.  pneumoniae  and  K.  oxytoca  strains
ere  subjected  to  antibiotic  sensitivity  tests  using
irby—Bauer’s  or  the  disk  diffusion  method  with  MH
gar as  detailed  previously  [20].  Similarly,  the  MIC
alues of  the  two  frequently  used  ﬂuoroquinolone
ntibiotics  ciproﬂoxacin  and  levoﬂoxacin  against  50
rug-sensitive  strains  and  50  resistant  strains  of  K.
xytoca and  K.  pneumoniae  were  also  determined.
tatistical analysis
he  statistical  analysis  was  performed  using  the
tatistical  Package  for  Medical  Science  version  17.0
SPSS Inc.,  IL).
esults
solation of K. oxytoca and K. pneumoniae
trains
 total  of  175  strains  of  K.  oxytoca  were  isolated
rom clinical  samples,  of  which  106  isolates  were
rom hospitalized  patients  and  69  isolates  were  CA
amples. Of  the  106  HA  strains,  67  isolates  were
SBL positive  and  71  strains  were  independently
esistant to  the  ﬂuoroquinolone  antibiotics.  Simi-
arly, of  the  69  CA  K.  oxytoca  strains,  37  isolates
ere ESBL-producing  strains  and  46  strains  were
T
l
sthesis represent number of ESBL producing isolates; numbers
lates.
ndependently  ﬂuoroquinolone  resistant  (Table  1).
 total  of  270  strains  of  K.  pneumoniae  were  iso-
ated, of  which  161  isolates  were  from  HA  samples
nd 109  isolates  were  from  CA  samples.  Several  of
he 270  isolates  were  also  resistant  to  K. oxytoca.
f  the  161  HA  strains,  113  K.  pneumoniae  isolates
ere ESBL-producing  strains  and  120  strains  were
ndependently  ﬂuoroquinolone  antibiotic  resistant.
imilarly,  of  the  109  CA  K.  pneumoniae  strains,
7 isolates  were  ESBL-producing  strains  and  75
trains were  independently  resistant  to  the  ﬂuoro-
uinolone  antibiotics  (Table  1).
iochemical identiﬁcation of K. oxytoca
nd K. pneumoniae strains
.  oxytoca  was  identiﬁed  based  on  the  colony
haracteristics on  cysteine  lactose  electrolyte-
eﬁcient (CLED)  and  MacConkey  agar,  together
ith the  results  of  9  biochemical  tests.  Yellow
ucoid colonies  on  CLED  agar  and  pink-colored
ucoid colonies  (Fig.  1)  on  MacConkey  agar
ere noted  because  of  lactose  fermentation.  Fur-
hermore,  positive  results  for  catalase,  indole,
oges—Proskauer,  citrate  urease  and  nitrate  reduc-
ion tests  and  negative  results  for  oxidase  and
ethyl-red were  conﬁrmatory.  For  the  triple  sugar
ron (TSI)  test,  the  bacterium  only  produced  acid,
ut no  gas  (Table  2).  Similarly,  the  K.  pneumo-
iae (Fig.  2)  strains  were  identiﬁed  based  on  the
olony  and  biochemical  characteristics  as  described
Table  2).  Both  strains  were  non-motile.
ntibiotic susceptibility patterns of K.
xytoca and K. pneumoniae strainshe  antibiotic  susceptibility  patterns  of  the  iso-
ated K.  oxytoca  and  K.  pneumoniae  strains  were
tudied  over  42  months  using  23  antibiotics.  The
500  S.  Rath,  R.N.  Padhy
Table  2  Microbiological  identiﬁcation  of  the  isolated  clinical  strains  of  K.  oxytoca  and  K.  pneumoniae.
Isolated  bacteria  MTCC  strain  Media  Colony  characters  Biochemical  characters
K.  oxytoca  2275  CLED  agar  Yellow,  mucoid Positive  for  catalase,  indole,  VP,  citrate,
urease  and  nitrate  tests.  Negative  for
oxidase  and  MR  tests.
TSI:  A/AG;  motility  was  negativeMacConkey  agar  LF,  pink,  mucoid
K.  pneumoniae  4031  CLED  agar  Yellow,  mucoid Positive  for  catalase,  VP,  citrate,  urease
and  nitrate  tests.  Negative  for  oxidase,
indole  and  MR  tests.
TSI:  A/AG;  motility  was  negative
MC  agar  LF,  pink,  mucoid
MR, methyl red; CLED, cysteine lactose electrolyte deﬁcient; LF, lactose fermenting; MTCC, microbial type culture collection; VP,
Voges—Proskauer; TSI, triple sugar iron; A/A, acid production both i
with gas.
Figure  1  Pink,  mucoid,  lactose  fermenting  colonies  of
K.  oxytoca  on  MacConkey  agar.
Figure  2  Yellow,  mucoid,  lactose  fermenting  colonies  of
K.  pneumoniae  on  CLED  agar.
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A  K.  oxytoca  strains  were  highly  resistant  to
efepime (89%),  followed  by  gatiﬂoxacin  (82%),
iproﬂoxacin  (78%),  and  ceftazidime  (76%)  and
ere least  resistant  to  imipenem  (23%).  Similarly,
he CA  K.  oxytoca  isolates  were  highly  resistant
o ciproﬂoxacin  (79%),  followed  by  gatiﬂoxacin
77%), ceﬁxime  (74%),  and  cefepime  (72%)  and  were
east resistant  to  imipenem  (15%)  and  levoﬂoxacin
21%) (Table  3). The  HA  K.  pneumoniae  strains
ere highly  resistant  to  ampicillin  (85%),  followed
y norﬂoxacin  (84%),  gatiﬂoxacin  (83%),  oﬂoxacin
83%),  amoxyclav  (82%),  and  cefepime  (81%)  and
ere least  resistant  to  imipenem  (21%).  The  CA
. pneumoniae  strains  were  also  highly  resistant
o ceftazidime  (79%),  followed  by  the  three  ﬂuo-
oquinolone  antibiotics,  ciproﬂoxacin,  gatiﬂoxacin,
nd norﬂoxacin  (all  at  74%),  cefepime,  ceﬁxime,
nd piperacillin  (all  at  71%)  and  were  the  least  resis-
ant to  imipenem  (19%).  The  resistance  percentage
alues clearly  indicate  the  occurrence  of  ESBL  and
uoroquinolone-resistant  strains  for  both  K.  oxy-
oca and  K.  pneumoniae  isolates  in  the  hospital
nd community  settings.  Moreover,  the  resistance
o imipenem  and  meropenem  (carbapenem  antibi-
tics) further  complicates  the  treatment  strategy  of
 clinician  because  these  are  the  most  recent  gen-
ration of  broad-spectrum  antibiotics  used  against
rug-resistant  pathogenic  bacteria  and  for  the
mpiric  therapy  of  critically  ill  patients.
IC values
ith  a  cohort  of  50  ESBL-producing  K.  oxy-
oca strains,  the  MIC  range  for  cefotaxime  was
4—256  g/ml  for  43  strains,  and  the  remaining  7
trains had  MIC  values  ≥512  g/ml.  Similarly,  for
eftazidime,  the  MIC  range  was  32—256  g/ml  for
2 strains,  and  the  remaining  18  strains  had  MIC
alues ≥512  g/ml.  These  MIC  values  conﬁrmed
Prevalence  of  two  multidrug-resistant  Klebsiella  species  501
Table  3  Percentage  of  resistance  of  K.  oxytoca  and  K.  pneumoniae  to  23  antibiotics  of  different  classes.
Antibiotic  group  Antibiotics  (g/disk)  Resistance  (in  %)
K.  oxytoca  K.  pneumoniae
HA  CA  HA  CA
Aminoglycosides Amikacin  30  51  39  74  57
Gentamicin  10 48 36  79  48
Netillin  30 52  48  46  35
-Lactams Amoxyclav  30 62 38  82  70
Ampicillin  10 67 43  85  71
Piperacillin  100  71  62  76  67
Piperacillin/tazobactam  100/10  49  35  67  49
Carbapenems Imipenem  10  23  15  21  19
Meropenem  10  45  49  36  31
Cephalosporins Cefepime  30 89 72  81  71
Ceﬁxime  30 68  74  66  71
Cefotaxime  30 64 47  62  57
Ceftazidime  30 76 58  65  79
Ceftriaxone  30 42 37  56  33
Cefuroxime  30  58  45  69  54
Fluoroquinolones Ciproﬂoxacin  5  78  79  80  74
Gatiﬂoxacin  5  82  77  83  74
Levoﬂoxacin  5  30  21  28  22
Norﬂoxacin  10  63  35  84  74
Oﬂoxacin  5  71  63  83  66
Monobactam  Aztreonam  30  46  33  76  43
Sulfonamides  Co-trimoxazole  25  51  45  59  45
t
t
≥
5Synthetic  drug  Nitrofurantoin  300  
HA, hospital acquired; CA, community acquired.he  presence  of  ESBL-producing  strains  because
he breakpoint  for  cefotaxime  and  ceftazidime  is
2 and  ≥4  g/ml,  respectively  [19]. Similarly,  all
0 non-ESBL  K.  oxytoca  isolates  were  in  the  MIC
r
c
K
t
Table  4  Detection  of  MIC  values  in  50  ESBL  producing  K.  oxy
cephalosporins  used  in  DDST.
Breakpoint
(g/ml)
K. oxytoca  
Cefotaxime  Ceftazidime  
ESBL
positive
(n  =  50)
ESBL
negative
(n =  50)
ESBL
positive
(n =  50)
ESBL
negativ
(n =  50)
≤0.25  —  01  —  —  
0.5  —  04  —  15  
1  —  10  —  18  
2  —  19  —  06  
4  —  16  —  06  
8  —  —  —  —  
16  —  —  —  —  
32  —  —  14  —  
64  12  —  06  —  
128  18  —  02  —  
256  13  —  10  —  
≥512  07  —  18  —  
DDST, double disk synergy test.48  35  71  49ange  of  0.5  to  4.0  g/ml  for  both  cefotaxime  and
eftazidime  (Table  4).  For  the  50  ESBL-producing
. pneumoniae  strains,  the  MIC  range  for  cefo-
axime was  64  to  256  g/ml  for  24  strains,  and  the
toca  and  K.  pneumoniae  strains  with  2  third-generation
K.  pneumoniae
Cefotaxime  Ceftazidime
e
ESBL
positive
(n =  50)
ESBL
negative
(n =  50)
ESBL
positive
(n =  50)
ESBL
negative
(n =  50)
—  —  —  —
—  11  —  17
—  21  —  19
—  18  —  12
—  —  —  —
—  —  —  —
—  —  —  —
—  —  —  —
06  —  23  —
08  —  07  —
10  —  12  —
26  —  08  —
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Table  5  Detection  of  MIC  values  in  50  ﬂuoroquinolone  resistant  producing  K.  oxytoca  and  K.  pneumoniae  strains
with  two  frequently  used  ﬂuoroquinolone  antibiotics.
Breakpoint
(g/ml)
K. oxytoca  K.  pneumoniae
Ciproﬂoxacin  Levoﬂoxacin  Ciproﬂoxacin  Levoﬂoxacin
Sensitive
(n  =  50)
Resistant
(n  =  50)
Sensitive
(n  =  50)
Resistant
(n  =  50)
Sensitive
(n  =  50)
Resistant
(n  =  50)
Sensitive
(n  =  50)
Resistant
(n  =  50)
≤0.25  25  —  09  —  18  —  21  —
0.5  17  —  13  —  11  —  17  —
1  08  —  28  —  21  —  12  —
2  —  03  —  —  —  —  —  —
4  —  09  —  20  —  —  —  —
8  —  05  —  03  —  15  —  06
16  —  10  —  —  —  10  —  —
32  —  —  —  —  —  03  —  —
64  —  16  —  09  —  09  —  29
128  —  02  —  13  —  01  —  12
256  —  01  —  —  —  10  —  03
≥512 —  04  —  —  —  02  —  —
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bremaining  26  strains  had  MIC  values  ≥512  g/ml.
Similarly,  for  ceftazidime,  the  MIC  range  was  42
to 256  g/ml  for  32  strains,  and  the  remaining  8
strains  had  MIC  values  ≥512  g/ml.  All  50  non-ESBL
K. pneumoniae  strains  were  in  the  MIC  range  of  0.5
to 2.0  g/ml  for  both  cefotaxime  and  ceftazidime.
Therefore,  all  50  strains  were  conﬁrmed  to  be  sus-
ceptible  to  both  antibiotics  (Table  4).
Furthermore,  with  the  50  ﬂuoroquinolone  sen-
sitive  K.  oxytoca  strains,  the  MIC  range  for
ciproﬂoxacin was  0.5—1.0  g/ml  for  25  strains,
and the  remaining  25  strains  had  MIC  values
≤0.25 g/ml.  For  levoﬂoxacin,  the  MIC  range  was
0.5—1.0 g/ml  for  28  strains,  and  the  remaining
22 strains  had  MIC  values  of  ≤0.25  g/ml.  These
MIC values  conﬁrmed  the  susceptibility  of  these  50
strains to  the  ﬂuoroquinolone  antibiotics  because
the breakpoints  for  ciproﬂoxacin  and  levoﬂoxacin
are ≥1  and  ≥2  g/ml,  respectively.  Of  the  50
ﬂuoroquinolone-resistant  K.  oxytoca  strains,  46  iso-
lates had  a  MIC  value  ranging  from  2  to  256  g/ml,
and the  remaining  4 isolates  had  a  MIC  value
≥512 g/ml  for  ciproﬂoxacin  (Table  5).  For  the  50
ﬂuoroquinolone  sensitive  K.  pneumoniae  strains,
the MIC  range  for  ciproﬂoxacin  was  0.5—1.0  g/ml
for 32  strains,  and  the  remaining  18  strains  had  MIC
values ≤0.25  g/ml.  For  levoﬂoxacin,  the  MIC  range
was 0.5—1.0  g/ml  for  29  strains,  and  the  remain-
ing 21  strains  had  MIC  values  of  ≤0.25  g/ml.  For
ciproﬂoxacin,  of  the  50  ﬂuoroquinolone-resistant  K.
pneumoniae  strains,  48  isolates  had  a  MIC  value
ranging  from  2  to  256  g/ml,  and  the  remain-
ing 2 isolates  had  a  MIC  value  ≥512  g/ml.  For
levoﬂoxacin, all  50  ﬂuoroquinolone-resistant  K.
s
c
aneumoniae  strains  had  MIC  values  in  the  range  of
—256 g/ml  (Table  5).
nivariate analysis
he  univariate  analysis  of  the  K.  oxytoca  ESBL
ositive and  negative  isolates  showed  that  the
cquisition  of  ESBL  positive  strains  in  a  hospital
etting was  1.4858  times  more  likely  than  from
he community  (Table  6).  This  value  was  0.5953
imes more  likely  for  hospital  settings  for  K.  pneu-
oniae  (Table  7).  Furthermore,  males  had  1.1693
imes more  chance  of  becoming  infected  with  K.
xytoca than  females  (Table  6).  Males  were  also
.8963  times  more  likely  than  females  to  become
nfected with  K.  pneumoniae  (Table  7).  Both  HA/CA
nd male/female  pairs  of  data  were  statistically
nsigniﬁcant.  Additionally,  comorbidities  from  non-
nfectious ailments  were  1.8261  and  4.0594  times
ore likely  for  ESBL  infections  with  any  Kleb-
iella species.  Patients  with  infections  were  0.1934
imes more  likely  to  become  infected  with  an  ESBL
train  for  K.  oxytoca,  whereas  they  were  0.0466
imes more  likely  to  become  infected  with  K.
neumoniae  (Table  7).  These  values  were  statisti-
ally  insigniﬁcant  for  K.  oxytoca  with  non-infectious
omorbidities,  whereas  they  were  signiﬁcant  for  K.
neumoniae. Similarly,  patients  with  infectious  ail-
ents were  likely  to  be  infected  with  ESBL  positive
acteria  at  highly  signiﬁcant  levels  (Tables  6  and  7).
For the  ﬂuoroquinolone-resistant  and  -sensitive
trains, K.  oxytoca  was  1.0143  times  more  likely  to
ause infection  in  a patient  in  the  hospital  setting,
nd a similar  likelihood  of  1.3268  was  determined
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Table  6  Univariate  analysis  of  ESBL  positive  and  negative  isolates  of  K.  oxytoca.
Variables  ESBL  positive  ESBL  negative  p-value  Odd  ratio  Range
Strains HA  67  39
0.2079* 1.4858
0.8023
—2.7515CA  37  32
Sex Male  71  46
0.6311* 1.1693
0.6175
—2.2143Female  33  25
Comorbidities Present  58  29
0.0535* 1.8261
0.9909
—3.3651Absent  46  42
Other  infections Present 36  52
<0.0001 0.1934
0.0997
—0.3753Absent  68  19
* Statistically not signiﬁcant.
Table  7  Univariate  analysis  of  ESBL  positive  and  negative  isolates  of  K.  pneumoniae.
Variables  ESBL  positive  ESBL  negative  p-value  Odd  ratio  Range
Strains HA  113  48
0.0780* 0.5953
0.3343
—1.0599CA  87  22
Sex Male  106  39
0.6951* 0.8963
0.5185
—1.5494Female  94  31
Comorbidities Present  127  21
<0.0001 4.0594
2.2577
—7.2989Absent  73  49
Infections Present  48  61
<0.0001 0.0466
0.0215
—0.1008Absent  152  09
* Statistically not signiﬁcant.
Table  8  Univariate  analysis  of  ﬂuoroquinolone  sensitive  and  resistant  isolates  of  K.  oxytoca.
Variables  Fq-S  Fq-R  p-value  Odd  ratio  Range
Strains HA  71  35
0.9656* 1.0143
0.5328
—1.9308CA  46  23
Sex Male  70  37
0.6127* 0.8453
0.4410
—1.6203Female  47  21
Comorbidities Present  65  19
0.0050 2.5658
1.3281
—4.9570Absent  52  39
Other  infections Present  27  41
<0.0001  0.1244
0.0611
—0.2531Absent  90  17
t.
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rFq-S, ﬂuoroquinolone sensitive; Fq-R, ﬂuoroquinolone resistan
* Statistically not signiﬁcant.
or  K.  pneumoniae  (Tables  8 and  9).  Males  had
.8453 (K.  oxytoca)  and  0.6320  (K.  pneumoniae)
imes more  risk  of  infection  by  ﬂuoroquinolone-
esistant  isolates  of  both  bacteria;  however,  these
alues were  not  statistically  signiﬁcant.  People  with
on-infectious  comorbidities  were  2.5658  (K.  oxy-
oca) and  1.7335  (K.  pneumoniae) times  more  likely
o become  infected,  and  people  with  infectious
omorbidities  were  0.1244  (K.  oxytoca)  and  0.5455
K. pneumoniae) times  at  more  risk  of  infection
ith ﬂuoroquinolone-resistant  isolates.  The  data
D
I
oor  the  non-infectious  or  infectious  comorbidities
ere highly  signiﬁcant  for  K.  oxytoca  and  moder-
tely signiﬁcant  for  K.  pneumoniae  (p  <  0.05).  In
onclusion,  K.  pneumoniae  had  a  higher  survival
ate than  K.  oxytoca.iscussion
n  a  surveillance  period  of  42  months,  445  strains
f both  K.  oxytoca  and  K.  pneumoniae  were
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Table  9  Univariate  analysis  of  ﬂuoroquinolone  sensitive  and  resistant  isolates  of  K.  pneumoniae.
Variables  Fq-S  Fq-R  p-value  Odd  ratio  Range
Strains HA 120  41
0.3033* 1.3268
0.7744
—2.2733CA  75  34
Sex Male  106  49
0.1037* 0.6320
0.3636
—1.0984Female  89  26
Comorbidities Present 115  34
0.0446 1.7335
1.0134
—2.9650Absent 80  41
Related  infections Present  117  55
0.0428 0.5455
0.3034
—0.9806Absent  78  20
Fq-S, ﬂuoroquinolone sensitive; Fq-R, ﬂuoroquinolone resistant.
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isolated  from  HA  and  CA  clinical  samples  to
determine the  prevalence  of  -lactam  and
ﬂuoroquinolone-resistant  strains.  The  antibiotic-
resistant patterns  of  both  Klebsiella  species  with
23 antibiotics  from  9  different  groups  were  ascer-
tained,  including  3GCs  and  a  monobactam.  Both
strains  were  highly  resistant  to  the  -lactam,
cephalosporin  and  ﬂuoroquinolone  antibiotics.  The
-lactam and  ﬂuoroquinolone-resistant  strains  of
both species  were  equally  prevalent.  A  univariate
analysis revealed  that  patients  with  other  bacterial
infections  had  relatively  higher  chances  of  infection
with ESBL-producing  and  ﬂuoroquinolone-resistant
strains  of  both  Klebsiella  species.
-Lactamase  enzymes  have  been  classiﬁed  by
Ambler et  al.  [21]  and  Bush  [22].  Ambler  pro-
posed four  classes  of  enzymes,  the  C,  A,  B  and
D -lactamases.  Ambler  class  C  belongs  to  group
1 (in  a  later  classiﬁcation)  with  51  enzymes.
Ambler classes  2a,  2b,  2be,  2br,  2c,  2d,  2e  and
2f include  256  enzymes,  such  as  broad-spectrum
-lactamase,  carbenicillin  hydrolyzing  enzymes,
clavulanate hydrolyzing  oxacillin,  carbapenem  and
cephalosporins.  Ambler  class  B  contains  Bush  group
3, consisting  of  metallo--lactamases,  which  are
not inhibited  by  clavulanate.  These  are  the  pri-
mary  groups  of  -lactam  antibiotics,  with  class  D
containing  Bush  group  4,  which  includes  enzymes
that are  not  grouped  with  the  other  enzyme
classes. This  group  of  enzymes  was  originally
detected in  the  GN  bacteria  P.  aeruginosa, Cit-
robacter  sp.  and  K.  pneumoniae  and  was  later
identiﬁed in  GP  bacteria.  GNs  with  ESBL-producing
capability  remain  susceptible  to  cefepime,  a
fourth-generation  cephalosporin,  and  carbapen-
ems.The ﬂuoroquinolone  group  is  the  preferred  class
of antibiotics  for  many  ailments,  such  as  respira-
tory, gastrointestinal,  urogenital,  intra-abdominal
and skin  infections  caused  by  GN  bacteria.  The
f
d
i
gmergence  of  quinolone  resistance  was  ﬁrst
eported in  K.  pneumoniae  and  has  rapidly  occurred
n S.  aureus  and  P.  aeruginosa  because  it  is  plasmid
orne  [23,24].  By  the  beginning  of  this  century,  the
ajority of  GN  and  GP  bacteria  acquired  quinolone
esistance [25,26]. Three  elements  are  involved  in
uinolone  resistance:  Qnr,  aminoglycoside  acetyl-
ransferase  AAC(6  )-Ib-cr,  and  OqxAB,  QepA  [27].
owever, nalidixic  acid  resistance  is  caused  by
he Qnr-protein,  which  reduces  the  susceptibility
o low  doses  of  ﬂuoroquinolones  [27].  In  an  ani-
al study,  lung  infection  with  K.  pneumoniae  was
reated with  marboﬂoxacin  (single  shot  adminis-
ration or  fractionated  regimen  over  4  days),  a
hird-generation  ﬂuoroquinolone  that  successfully
reated the  infection,  but  resistant  strains  of  the
ame bacterium  emerged  in  the  gut  ﬂora  [28].
Carbapenem resistance  occurs  in  both  GP  and
N bacteria.  Carbapenem-resistant  Enterobacte-
iaceae, particularly  Klebsiella  species,  may  be
ew superbugs  because  carbapenem  is  the  last
ine of  defense  for  drug-resistant  Klebsiella. Fail-
re of  all  other  classes  of  antibiotics  can  be
ddressed by  carbapenems  only.  Uncontrollable
epsis and  bloodstream  infections  arising  exclu-
ively  from  drug-resistant  Enterobacteriaceae  are
ontrolled exclusively  by  carbapenem  antibiotics.
he high  meropenem  resistance,  30—50%  in  the  hos-
ital evaluated  in  this  study,  is  troubling.  Despite
he repeated  warnings  from  clinical  failures,  our
ntimicrobial  stewardship  is  inadequate.  However,
here are  several  controllable  and  uncontrollable
actors involved  in  the  emergence  and  spread
f carbapenem  resistance  in  the  hospital  and
djoining  community.  Hospitals  everywhere,  par-
icularly in  developing  tropical  countries,  should
ocus  on  carbapenem  resistance.  An  excellent  study
escribes the  primary  genetic  structures  involved
n the  acquisition  of  the  carbapenemase-resistant
ene  for  all  Enterobacteriaceae  members  and  the
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istribution  of  the  genes  responsible  for  resistance
n the  Ambler  classes  A,  B  and  D  [29].  The  carbapen-
mase genes  SME-1  to  3,  NMC-A,  IMI-2,  GES-4,5,6,
PC-2 to  12,  IMP-1  to  -13,  VIM-1  to  -33,  NDM-1  to  -6,
HM-1, OXA  48,  and  OXA-181  have  been  described
29]  and  may  be  chromosomal  or  plasmid  borne.
he majority  of  carbapenemases  are  inhibited  by
lavulanate,  tazobactam,  sulbactam  and  NXL-104
ut rarely  by  boronic  acid,  EDTA  and  NaCl.
In a  Korean  study,  drug  resistance  in  GN  bacte-
ia was  observed  for  ﬂuoroquinolone  resistance  in
. coli  (27%),  P.  aeruginosa  (33%)  and  Acinetobac-
er sp.  (48%),  whereas  amikacin  resistance  occurred
n P.  aeruginosa  (19%)  and  Acinetobacter  sp.  (37%).
GC resistance  was  observed  in  K.  pneumoniae
29%) [30].  Vancomycin-resistant  Enterococcus  fae-
ium was  also  reported,  and  imipenem  resistance  in
cinetobacter  sp.  gradually  increased  in  the  hospi-
al. E.  coli,  Acinetobacter  sp.,  P.  aeruginosa  and  S.
ureus were  the  most  prevalent  MDR  bacteria  [30].
he detection  of  plasmid-mediated  quinolone  resis-
ance in  clinical  isolates  of  hospitalized  patients
n Spain  was  reported  for  the  qnrB5  and  qnrB2
enes,  both  in  K.  oxytoca  and  Enterobacter  cloa-
ae, and  the  former  gene  showed  higher  prevalence
31].  A  report  from  Iraq  of  a  hospital  based
tudy of  259  under-5  children  showed  that  2.4%
f the  children  had  nosocomial  diarrhea  caused
y Enterobacter  sp.,  P.  aeruginosa  and  Citrobac-
er sp.  These  incidences  of  diarrhea  were  linked
o unclean  food,  contaminated  bedsheets  and  per-
onal hygiene  affecting  breast-feeding,  and  in  all
ases, contaminated  hands  played  a  signiﬁcant  role
32].  To  decrease  ESBL  prevalence  in  a  hospital  or
ommunity,  3GC  antibiotic  use  in  non-hospitalized
atients must  also  be  reduced  because  the  use  of
GC or  3GC  increases  the  risk  of  fecal  carriage  of
SBL producers  by  2—4-fold  [33].  Gastrointestinal
arriage of  K.  pneumoniae  had  been  reported  as
he predisposing  factor  of  pyogenic  liver  abscess
n Taiwan.  Molecular  typing  of  isolated  K.  pneumo-
iae strains  of  the  different  serotypes  K1  and  K2
ith rampA  genes  concluded  that  virulence  deter-
inants  result  in  this  ailment  [34].  Furthermore,
. pneumoniae  serotypes  K1  and  K2  account  for
8% of  isolates  from  all  countries  and  correspond  to
he serotypes  isolated  from  liver  abscesses  in  Asian
ountries  [35].  Except  for  Clostridium  difﬁcile,
osocomial  diarrhea  is  caused  by  other  infec-
ious agents,  such  as,  norovirus  and  toxicogenic
trains of  Clostridium  perfringens, K.  oxytoca,  S.
ureus and  Bacteroides  fragilis  [36]. Moreover,
he fatality  caused  by  Klebsiella  sp.  and  other
nterobacteriaceae  remains  consistently  high,  with
alues of  16—37%  in  Thailand  a  decade  ago.
ecently the  mortality  of  Klebsiella  sp.  and  other
E
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nterobacteriaceae  members  was  determined  to
e 37.5%  [37]. Recently,  in  Saint-Etienne,  France,
t was  reported  that  ESBL-producing  K.  pneumo-
iae strains  contained  blaCTXm-15  genes,  causing
acterial  resistance  to  ceftazidime,  ciproﬂoxacin
nd tobramycin  in  ICU  patients  [38]. Antibiotic-
ssociated hemorrhagic  colitis  was  associated  with
. oxytoca  strains  isolated  from  stool  samples  in
ustria. Because  K.  oxytoca  is  an  opportunistic
athogen,  acquired  drug  resistance  after  antibi-
tic use  may  replace  normal  colonic  micro  ﬂora
ith virulent  strains.  Therefore,  adverse  effects
n the  normal  gut  ﬂora  can  occur  after  antibi-
tic therapy.  However,  C.  difﬁcile  is an  aggressive
nteropathogen,  and  its  MDR  strains  did  not  cause
ntibiotic-associated  hemorrhagic  colitis  [39,40].
hese infectious  situations  caused  by  Klebsiella  sp.
n diverse  geographic  zones  demonstrate  that  these
re clonally  different  and  peripatetic.
In particular,  elderly  patients  admitted  to
ospitals are  generally  multi-morbid  and  have
educed  immune-competence.  They  are  increas-
ngly susceptible  to  antibiotic-resistant  bacteria.
SBL-carrying  patients  have  longer  hospital  stays
nd use  of  hospital  devices  for  prolonged  peri-
ds, which  arise  from  and  lead  to  illness  from  an
nfection  with  concomitant  exposure  to  nosocomial
nfections with  other  pathogens.  Eventually,  newer
ntibiotics  are  be  used  [41,42], ultimately  leading
o multidrug-resistant  bacteria.
In conclusion,  among  the  Enterobacteriaceae,
oth  species  of Klebsiella  had  an  alarming  infec-
ion dynamics  and  were  resistant  to  the  3GCs  and
uoroquinolones.  The  K.  pneumoniae  strains  were
esistant  to  a greater  number  of  antibiotics,  and  the
ercent resistance  values  for  each  antibiotic  were
igher with  the  isolated  strains.
unding
.  Rath  is  a Senior  Research  Fellow  for  a  project
rom the  Council  of  Scientiﬁc  and  Industrial
esearch, New  Delhi  [grant  no.  21  (0859)/11/EMR-
I], awarded  to  R.N.  Padhy.
ompeting interests
one  declared.thical approval
ot  required.
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[506  
Authors’ contributions
S.R.  and  R.N.P.  conceived  and  designed  the  study.
S.R. collected,  analyzed  and  interpreted  the  data.
Both S.R.  and  R.N.P.  were  involved  in  drafting  the
manuscript.  All  authors  read  the  manuscript  and
approved  the  ﬁnal  copy  for  submission.
Acknowledgements
We  are  grateful  to  the  Department  of  Microbiol-
ogy, IMS  &  Sum  Hospital,  Bhubaneswar,  for  use  of
the facilities.  This  work  is  a  part  of  Ph.D.  thesis  in
microbiology  of  S.  Rath,  Utkal  University.
References
[1] Pitout JD, Thomson KS, Hanson ND, Ehrhardt AF, Moland
ES, Sanders CC. -Lactamases responsible for resistance
to expanded-spectrum cephalosporins in Klebsiella pneu-
moniae, Escherichia coli, and Proteus mirabilis isolates
recovered in South Africa. Antimicrob Agents Chemother
1998;42:1350—4.
[2] Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of
Klebsiella pneumoniae carbapenemase-producing K. pneu-
moniae to upstate New York. Clin Infect Dis 2006;43:26—8.
[3] Rodríguez-Ban˜o J, Navarro MD, Retamar P, Picón E, Pascual
A, the extended-spectrum beta-lactamases—red espan˜ola
de investigación en patología infecciosa/grupo de estudio
de infección hospitalaria group. Risk factors and prognosis
of nosocomial bloodstream infections caused by extended-
spectrum-beta-lactamase-producing Escherichia coli. J Clin
Microbiol 2010;48:1726—31.
[4] Dubey D, Sarangi R, Debata NK, Padhy RN. Detection of
metallo--lactamase producing Klebsiella pneumoniae in a
neonatal septicemia. J Acute Dis 2013;2:82—4.
[5] Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative
bacteria: the dawn of the post-antibiotic era? Int J Antimi-
crob Agents 2007;29:630—6.
[6] Pitout JD, Laupland KB. Extended-spectrum -lactamase
producing Enterobacteriaceae: an emerging public-health
concern. Lancet Infect Dis 2008;8:159—66.
[7] Schwaber MJ, Carmeli Y. Mortality and delay in effec-
tive therapy associated with extended-spectrum-beta-
lactamase production in Enterobacteriaceae bacteraemia:
a systematic review and meta-analysis. J Antimicrob
Chemother 2007;60:913—20.
[8] Tumbarello M, Spanu T, Di Bidino R, Ruggeri M, Tre-
carichi EM, De Pascale G, et al. Costs of bloodstream
infections caused by Escherichia coli and inﬂuence of
extended-spectrum-beta-lactamase production and inad-
equate initial antibiotic therapy. Antimicrob Agents
Chemother 2010;54:4085—91.
[9] Cheong HS, Ko KS, Kang CI, Chung DR, Peck KR,
Song JH. Clinical signiﬁcance of infections caused by
extended-spectrum-beta-lactamase-producing Enterobac-
teriaceae blood isolates with inducible AmpC -lactamase.
Microb Drug Resist 2012;18:446—52.
[10] Hooper DC. Emerging mechanisms of ﬂuoroquinolone resis-
tance. Emerg Infect Dis 2001;7:337—41.
[S.  Rath,  R.N.  Padhy
11] Wetzstein HG, Schmee N, Karl W. Degradation of the
ﬂuoroquinolone enroﬂoxacin by the brown rot fungus
Gloeophyllum striatum: identiﬁcation of metabolites. Appl
Environ Microbiol 1997;63:4272—81.
12] Parshikov IA, Freeman JP, Lay Jr JO, Beger RD, Williams
AJ, Sutherland JB. Microbiological transformation of
enroﬂoxacin by the fungus Mucor ramannianus. Appl Envi-
ron Microbiol 2000;66:2664—7.
13] Nazik H, Ongen B, Ilktac M, Aydin S, Kuvat N, Sahin A,
et al. Carbapenem resistance due to bla(OXA-48) among
ESBL-producing Escherichia coli and Klebsiella pneumoniae
isolates in a university hospital, Turkey. Southeast Asian J
Trop Med Public Health 2012;43:1178—85.
14] Sahu MC, Dubey D, Rath S, Debata NK, Padhy RN. Mul-
tidrug resistance of Pseudomonas aeruginosa as known
from surveillance of nosocomial and community infections
in an Indian teaching hospital. J Public Health 2012;20:
413—23.
15] Arslan H, Azap OK, Ergonul O, Timurkaynak F. Urinary
tract infection study group: risk factors for ciproﬂoxacin
resistance among Escherichia coli strains isolated from
community-acquired urinary tract infections in Turkey. J
Antimicrob Chemother 2005;56:914—8.
16] Muratani T, Matsumoto T. Urinary tract infection caused
by ﬂuoroquinolone- and cephem-resistant Enterobacteri-
aceae. Int J Antimicrob Agents 2006;28:10—3.
17] Rath S, Padhy RN. Surveillance of multidrug resistance of 10
enteropathogens in a teaching hospital and in vitro efﬁcacy
of 25 ethnomedicinal plants used by an Indian aborigine.
Asian Pac J Trop Dis 2012;2:S336—46.
18] Rath S, Padhy RN. Monitoring in vitro antibacterial
efﬁcacy of Terminalia alata Heyne ex. Roth, against mul-
tidrug resistant enteropathogenic bacteria. J Acute Med
2013;3:93—102.
19] EUCAST. The European committee of antimicrobial suscep-
tibility testing. Breakpoint tables for interpretation of MICs
and zone diameters; 2013, 3.1.
20] Rath S, Dubey D, Sahu MC, Debata NK, Padhy RN. Surveil-
lance of ESBL producing multidrug resistant Escherichia
coli in a teaching hospital in India. Asian Pac J Trop Dis
2014;4:140—9.
21] Ambler RP, Coulson AF, Frere JM, Ghuysen JM, Joris B,
Forsman M, et al. A standard numbering scheme for the
class-A-beta-lactamases. Biochem J 1991;276:269—70.
22] Bush K, Jacoby G, Medeiros AA. A functional classiﬁcation
scheme for -lactamases and its correlation with molecu-
lar structure. Antimicrob Agents Chemother 1995;39:1211—
23.
23] Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa
and Staphylococcus aureus:  development during therapy
and clinical signiﬁcance. Infection 1994;22:111—21.
24] Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resis-
tance from a transferable plasmid. Lancet 1998;351:797—9.
25] Dalhoff A, Schmitz FJ. In vitro antibacterial activity and
pharmacodynamics of new quinolones. Eur J Clin Microbiol
Infect Dis 2003;22:203—21.
26] Robicsek A, Jacoby GA, Hooper DC. The worldwide emer-
gence of plasmid-mediated quinolone resistance. Lancet
Infect Dis 2006;6:629—40.
27] Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated
quinolone resistance a clinically signiﬁcant problem? Clin
Microbiol Infect 2008;14:295—7.
28] Kesteman AS, Perrin-Guyomard A, Laurentie M, Sanders P,
Toutain PL, Bousquet-Mélou A. Emergence of resistant Kleb-
siella pneumoniae in the intestinal tract during a successful
treatment of Klebsiella pneumoniae lung infection in rats.
Antimicrob Agents Chemother 2010;54:2960—4.
P ecie
[
[
[
[
[
[
[
[
[
[
[
[
[revalence  of  two  multidrug-resistant  Klebsiella  sp
29] Nordmann P, Dortet L, Poirel L. Carbapenem resistance
in Enterobacteriaceae: here is the storm. Trends Mol Med
2012;18:263—72.
30] Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, et al. Increase
of ceftazidime- and ﬂuoroquinolone-resistant Klebsiella
pneumoniae and imipenem-resistant Acinetobacter spp. in
Korea: analysis of Konsar study data from 2005 and 2007.
Yonsei Med J 2010;51:901—11.
31] Cano ME, Rodríguez-Martínez JM, Agüero J, Pascual A, Calvo
J, García-Lobo JM, et al. Detection of plasmid-quinolone
resistance genes in clinical isolates of Enterobacter spp. in
Spain. J Clin Microbiol 2009;47:2033—9.
32] Alrifai SB, Saadi AA, Mahmood YA. Nosocomial diarrhoea
in relation to sanitation state: a study in Tikrit, Iraq. East
Mediterr Health J 2010;16:546—52.
33] Kiremitc¸i  A, Dinleyici CE, Yargıc¸  ZA, Durmaz G, Tekin
N. Prevalence and risk factors of fecal carriage of
extended-spectrum -lactamase (ESBL)-producing Enter-
obacteriaceae in hospitalized and ambulatory children. J
Pediatr Infect 2011;5:54—8.
34] Fung CP, Lin YT, Lin JC, Chen TL, Yeh KM, Chang FY,
et al. Klebsiella pneumoniae in gastrointestinal tract
and pyogenic liver abscess. Emerg Infect Dis 2012;18:
1322—5.
35] Lin YT, Siu LK, Lin JC, Chen TL, Tseng CP, Yeh KM, et al.
Seroepidemiology of Klebsiella pneumoniae colonizing the
intestinal tract of healthy Chinese and overseas Chi-
nese adults in Asian countries. BMC Microbiol 2012;12:13,
http://dx.doi.org/10.1186/1471-2180-12-13.
[
Available  online  at  www
ScienceDs  507
36] Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhoea:
evaluation and treatment of causes other than Clostridium
difﬁcile. Clin Infect Dis 2012;55:982—9.
37] Kanoksil M, Jatapai A, Peacock SJ, Limmathurotsaku D.
Epidemiology, microbiology and mortality associated with
community-acquired bacteremia in northeast Thailand: a
multicenter surveillance study. PLOS ONE 2013;8:e54714.
38] Filippa N, Carricajo A, Grattard F, Fascia P, Sayed FE, Deﬁl-
ippis JP, et al. Outbreak of multidrug-resistant Klebsiella
pneumoniae carrying qnrB1 and blaCTX-M15 in a French
intensive care unit. Ann Intensive Care 2013;3:18—21.
39] Joainig MM, Gorkiewicz G, Leitner E, Weberhofer P, Zollner-
Schwetz I, Lippe I, et al. Cytotoxic effects of Klebsiella
oxytoca strains isolated from patients with antibiotic-
associated hemorrhagic colitis or other diseases caused
by infections and from healthy subjects. J Clin Microbiol
2010;48:817—24.
40] Hoffmann KM, Deutschmann A, Weitzer C, Joainig M,
Zechner E, Högenauer C, et al. Antibiotic-associated hem-
orrhagic colitis caused by cytotoxin-producing Klebsiella
oxytoca. Pediatrics 2010;125:e960.
41] Mangeney N, Niel P, Paul G, Faubert E, Hue S, Dupeyron C,
et al. A 5-year epidemiological study of extended-spectrum
beta-lactamase-producing Klebsiella pneumoniae isolates
in a medium- and long-stay neurological unit. J Appl Micro-
biol 2000;88:504—11.42] WHO. The burden of health care-associated infection
worldwide; 2011. Available at: http://www.who.int/gpsc/
country work/summary 20100430 en.pdf
.sciencedirect.com
irect
